Form 4: Bausch & Lomb EVP and CFO Sam Eldessouky Reports Stock and Option Grants

Sam Eldessouky, EVP and CFO of Bausch & Lomb, reports the acquisition of restricted stock units and stock options.

Summary

• Sam Eldessouky, the EVP and CFO of Bausch & Lomb Corp, filed a Form 4 on March 1, 2024, reporting transactions related to the company's stock.
• On February 28, 2024, Eldessouky acquired 50,335 common shares in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs vest in equal installments over three years from the grant date.
• Also on February 28, 2024, Eldessouky acquired 152,439 non-qualified stock options with an exercise price of $16.85.
• These options also vest in equal installments over three years and expire ten years from the grant date.
• Following these transactions, Eldessouky directly owns 248,634 common shares and 152,439 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing executive compensation. The grants themselves are a positive sign of aligning management with shareholder interests, but the filing itself is simply a factual disclosure.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The RSUs and stock options are subject to continued service and the terms of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in publicly traded companies, particularly in the pharmaceutical and healthcare sectors.
• Companies like Johnson & Johnson, Novartis, and AbbVie also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and terms of these grants are generally in line with industry standards, designed to retain key personnel and align their interests with long-term shareholder value.

Stakeholder Impact

• The grants align management's interests with shareholders, potentially driving long-term value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates